DE3310079C2 - - Google Patents

Info

Publication number
DE3310079C2
DE3310079C2 DE3310079A DE3310079A DE3310079C2 DE 3310079 C2 DE3310079 C2 DE 3310079C2 DE 3310079 A DE3310079 A DE 3310079A DE 3310079 A DE3310079 A DE 3310079A DE 3310079 C2 DE3310079 C2 DE 3310079C2
Authority
DE
Germany
Prior art keywords
eye
ophthalmic
compounds
cornea
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3310079A
Other languages
German (de)
English (en)
Other versions
DE3310079A1 (de
Inventor
David Lowell San Mateo Calif. Us Waterbury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of DE3310079A1 publication Critical patent/DE3310079A1/de
Application granted granted Critical
Publication of DE3310079C2 publication Critical patent/DE3310079C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE19833310079 1982-03-22 1983-03-21 Topische ophthalmische arzneimittel Granted DE3310079A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/360,754 US4454151A (en) 1982-03-22 1982-03-22 Use of pyrrolo pyrroles in treatment of ophthalmic diseases

Publications (2)

Publication Number Publication Date
DE3310079A1 DE3310079A1 (de) 1983-09-22
DE3310079C2 true DE3310079C2 (enExample) 1990-10-18

Family

ID=23419287

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19833310079 Granted DE3310079A1 (de) 1982-03-22 1983-03-21 Topische ophthalmische arzneimittel

Country Status (6)

Country Link
US (1) US4454151A (enExample)
JP (1) JPS58172314A (enExample)
AU (1) AU568072B2 (enExample)
DE (1) DE3310079A1 (enExample)
IT (1) IT1162842B (enExample)
NZ (1) NZ203639A (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4826869A (en) * 1988-02-19 1989-05-02 Syntex (U.S.A.) Inc. N-(lower alkyl)-2-(3'ureidobenzyl)pyrrolidines
US5124392A (en) * 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5271939A (en) * 1988-10-03 1993-12-21 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US4939135A (en) * 1988-10-03 1990-07-03 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
BR9107284A (pt) * 1990-12-27 1994-09-27 Allergan Inc Processo para desinfetar lentes de contato, e, solução desinfetante de lentes de contato.
US5207660A (en) * 1991-04-26 1993-05-04 Cornell Research Foundation, Inc. Method for the delivery of compositions to the ocular tissues
ATE181667T1 (de) * 1991-11-11 1999-07-15 Hisamitsu Pharmaceutical Co Ketorolac enthaltender warmer umschlag
WO1994009777A1 (en) * 1992-10-30 1994-05-11 Syntex (U.S.A.) Inc. Transdermal delivery of ketorolac
US5629345A (en) * 1993-07-23 1997-05-13 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
EP0707465A4 (en) * 1993-07-08 1997-04-16 Cygnus Therapeutic Systems MONOLITHIC MATRIX TRANSDERMAL DELIVERY SYSTEM
US5965620A (en) * 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US6191285B1 (en) 1997-07-03 2001-02-20 Abbott Laboratories Process for the preparation of ketorolac tromethamine
US6309374B1 (en) 1998-08-03 2001-10-30 Insite Vision Incorporated Injection apparatus and method of using same
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6552020B1 (en) 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
KR100854058B1 (ko) * 2001-03-28 2008-08-26 산텐 세이야꾸 가부시키가이샤 스테로이드를 유효 성분으로 하는 망맥락막 질환 치료제
US6646003B2 (en) 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US8008338B2 (en) 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
JP2008520589A (ja) * 2004-11-17 2008-06-19 ジョアン マクローリン， シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法
WO2007119108A2 (en) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20090010850A1 (en) * 2007-05-24 2009-01-08 Ousler Iii George W Formulations and methods for treating dry eye
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
WO2007087609A2 (en) * 2006-01-25 2007-08-02 Aciex, Inc. Formulations and methods for treating dry eye
CA2642647A1 (en) * 2006-02-17 2007-11-15 Joanne Mclaurin Compositions and methods for treatment of disorders of protein aggregation
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
EP1996175A4 (en) * 2006-03-09 2009-06-10 Waratah Pharmaceuticals Inc CYCLOHEXAN POLYALKOHOL FORMULATION FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
MX2008013783A (es) * 2006-04-26 2009-02-05 Aciex Inc Composiciones para el tratamiento y prevención de la hinchazón de los párpados.
US20090136598A1 (en) * 2006-04-26 2009-05-28 Aciex, Inc. Compositions for the Treatment and Prevention of Eyelid Swelling
WO2007134449A1 (en) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
WO2008061373A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and similar diseases
AU2008219600A1 (en) * 2007-02-28 2008-09-04 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions
US20100168250A1 (en) 2007-04-12 2010-07-01 Antonio Cruz Use of cyclohexanehexol derivatives in the treatment of ocular disease
US20100331267A1 (en) * 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
US20100144891A1 (en) * 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
CA2683548A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
US20090018057A1 (en) * 2007-07-09 2009-01-15 Gregory Lambert OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
RU2359658C1 (ru) * 2008-02-22 2009-06-27 Ирина Александровна Глущенко Средство для профилактики и лечения офтальмологических заболеваний
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
WO2010040232A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
US8778999B2 (en) 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
HUE060464T2 (hu) 2013-03-13 2023-03-28 Genzyme Corp PDGF- és VEGF-kötõrészeket tartalmazó fúziós fehérjék és eljárások azok alkalmazására
HK1231496A1 (zh) 2014-06-20 2017-12-22 豪夫迈．罗氏有限公司 基於chagasin的支架组合物、方法和应用
AU2024297654A1 (en) 2023-07-13 2026-01-22 Kriya Therapeutics, Inc. Complement pathway inhibitor fusions and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087539A (en) * 1976-07-14 1978-05-02 Syntex (U.S.A.) Inc. 5-(2-Furoyl)-, 5-(2-thenoyl)-, 5-(3-furoyl)- and 5-(3-thenoyl)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4097579A (en) * 1977-03-31 1978-06-27 Syntex (U.S.A.) Inc. 5-(2-Pyrroyl)-1,2-dihydro-3H-pyrrolo 1,2-a!pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4140698A (en) * 1977-07-25 1979-02-20 Syntex (Usa) Inc. 1,2-Dihydro-3H-pyrrolo[1,2-a]pyrrole-1-nitriles
US4232038A (en) * 1979-08-31 1980-11-04 Syntex (U.S.A.) Inc. 5-Alkylsulfinylbenzoyl- and 5-alkylsulfonylbenzoyl-1,2-dihydro-3H-pyrrolo[1,]pyrrole-1-carboxylic acids
US4344943A (en) * 1980-06-09 1982-08-17 Syntex (U.S.A.) Inc. 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo[1,2-a]-pyrrole-1-carboxylic acids and derivatives thereof

Also Published As

Publication number Publication date
AU568072B2 (en) 1987-12-17
IT8367315A0 (it) 1983-03-21
US4454151A (en) 1984-06-12
JPS58172314A (ja) 1983-10-11
JPH047324B2 (enExample) 1992-02-10
AU1265183A (en) 1983-09-29
DE3310079A1 (de) 1983-09-22
NZ203639A (en) 1988-05-30
IT1162842B (it) 1987-04-01

Similar Documents

Publication Publication Date Title
DE3310079C2 (enExample)
DE68902649T2 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
US4452818A (en) Extraocular method of treating the eye with liquid perfluorocarbons
DE69630325T2 (de) Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern
DE69326610T2 (de) Arzneimittel gegen glaukom
JPH01104023A (ja) 眼用保存製剤およびその製法
DE69208941T2 (de) Augenpräparate mit verlängerter Freigabe
JPH04221322A (ja) 眼病用製剤
DE69721824T2 (de) Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen
DE60013126T2 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
EP0585896B1 (de) Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
US4459309A (en) Compositions and methods of lowering intraocular pressure in the hypertensive mammalian eye
DE69921678T2 (de) Zusammensetzung enthaltend di- und trinatriumsalze von echinochrome zur behandlung von augenerkrankungen
EP0410749B1 (en) Anthocyanidins for the treatment of ophthalmic diseases
Vale et al. Drugs and the Eye: Sponsored by the British Optical Association
DE69227324T2 (de) Pharmazeutische zusammensetzung, die carbachol und andere cholinerge substanzen enthält
DE10360425A1 (de) Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
DE3688503T2 (de) Erhöhung des ausfliessens wässriger körperfluessigkeit.
DE60213230T2 (de) Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit
US4477460A (en) Topical treatment of ocular hypertension
ELLIS et al. Comparative intraocular levels of pilocarpine achieved with drops and repository preparations
CA2929965C (en) Method and composition for treating glaucoma
US20240299291A1 (en) Ophthalmic preparation administered by eye drops and used for preventing and treating dry macular degeneration and retinal light damage
DE69113675T2 (de) Verwendung von Naproxen als Mydriatikum.
de ROETTH Ophthalmic pharmacology and toxicology

Legal Events

Date Code Title Description
8101 Request for examination as to novelty
8105 Search report available
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: BARZ, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 80803 MUENCHEN